CLINICAL_TRIALS
trial_result
· 2022-11-23
Clinical Trial Update: A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) [Phase 3]
Summary
Phase 3 trial update for baricitinib in systemic lupus erythematosus (SLE) completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2022-11-23